SCYNEXIS awarded $214M non-dilutive BARDA funding to advance SCY-247 antifungal candidate into Phase II trials for serious ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results